An investigation into the morphology of loxapine in a thermal aerosolization process from crystalline to amorphous

Journal of Pharmaceutical Sciences

Volumn 100, Issue 4, 2011, Pages 1407-1415

  Gao, Qiufeng ^a   Lew, Angela ^a   Takahashi, Lori H ^a   Cassella, James V ^a  

^a Alexza Pharmaceuticals   (United States)

Author keywords

Aerosol; FTIR; Loxapine; Polymorph; Raman spectroscopy; XRD

Indexed keywords

LOXAPINE; AEROSOL; NEUROLEPTIC AGENT;

AEROSOL; ARTICLE; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG STRUCTURE; INFRARED SPECTROSCOPY; PHYSICAL CHEMISTRY; POWDER DIFFRACTION; RAMAN SPECTROMETRY; THERMAL ANALYSIS; X RAY DIFFRACTION; CHEMISTRY; CRYSTALLIZATION;

AEROSOLS; ANTIPSYCHOTIC AGENTS; CRYSTALLIZATION; LOXAPINE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SPECTRUM ANALYSIS, RAMAN; X-RAY DIFFRACTION;

EID: 79951915473     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22364     Document Type: Article

References (14)

1. Lee SL, Adams WP, Li BV, Conner DP, Chowdhury BA, Yu LX. 2009. In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases. AAPS J 11(3):414-423.
2. Rabinowitz JD, Wensley M, Lloyd P, Myers D, Shen W, Lu A, Hodges C, Hale R, Mufson D, Zaffaroni A. 2004. Fast onset medications through thermally generated aerosols. J Pharmacol Exp Ther 309:769-775.
3. Rabinowitz JD, Lloyd PM, Munzar P, Myers DJ, Cross S, Damani R, Quintana R, Spyker DA, Soni P, Cassella JV. 2006. Ultra-fast absorption of amorphous pure drug aerosols via deep lung inhalation. J Pharm Sci 95(11):2438-2451.
4. Nordstrom K. 2009. Drug evaluation inhaled loxapine for acute agitation in schizophrenia and bipolar disorder. Future Neurol 4(5):539-545.
5. Cosulich DB, Lovell FM. 1977. The X-ray crystal structures of loxapine 2-chloro-11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepine and amoxapine 2-chloro-11-(1-piperazinyl)dibenz[b, f][1, 4]oxazepine. Acta Cryst B 33:1147-1154.
6. Petcher TJ, Weber HP. 1976. Conformations of some semi-rigid neuroleptic drugs. Part 1. Crystal structures of loxapine, clozapine, and HUF-2046 monohydrate 2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b, f][1, 4]oxazepine, 8-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b, e][1, 4]diazepine, and 2-chloro-11(4-methylpiperazin-1-yl)dibenzo[b, e][1, 4]diazepine monohydrate. J Chem Soc Perkin Trans 2:1415-1420.
7. Myers DJ, Timmons RD, Lu AT, Hale RL, Solas DW, Soni P, Rabinowitz JD. 2007. The effect of film thickness on thermal aerosol generation. Pharm Res 24(2):336-342.
8. Salari A, Young RE. 1998. Application of attenuated total reflectance FTIR spectroscopy to the analysis of mixtures of pharmaceutical polymorphs. Int J Pharm 163(1-2):157-166.
9. Yalkowsky S. 1999. Solubility and solubilization in aqueous media. Washington DC: ACS.
10. Spyker DA, Munzar P, Cassella JV. 2010. Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. J Clin Pharmacol 50(2):169-179.
11. Dinh KV, Myers DJ, Noymer PD, Cassella JV. 2010. In vitro aerosol deposition in the oropharyngeal region for Staccato® loxapine. J Aerosol Med Pulm D 23(4):1-8.
12. Heyder J. 1982. "Particle transport onto human airway surfaces." Eur J Respir Dis Suppl 119:29-50.
13. Avram MJ, Spyker DA, Henthorn TK, Cassella JV. 2009. The pharmacokinetics and bioavailability of prochlorperazine delivered as a thermally generated aerosol in a single breath to volunteers. Clin Pharmacol Ther 85(1):71-77.
14. Blagden N, deMatas M, Gavan PT, York P. 2007. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev 59(7):617-630.